Patents by Inventor Yunhai Cui
Yunhai Cui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240164532Abstract: The present application relates to a sofa unfolding device capable of avoiding forward overturning, including a seat, a backrest assembly, a linkage assembly, and a leg rest assembly, wherein the linkage assembly is rotatably connected on the seat, the backrest assembly is rotatably connected to a rear end of the seat via the linkage assembly, the leg rest assembly is rotatably connected to a front end of the seat via the linkage assembly, a support mechanism is connected on the front end of the seat and comprises an abutting member and a support member, the abutting member is rotatably connected with the linkage assembly via a first pivot, and the support member is rotatably connected with the abutting assembly via a second pivot and is rotatably connected with the seat via a third pivot.Type: ApplicationFiled: June 5, 2023Publication date: May 23, 2024Inventors: Yunhai LI, Yuanfeng FENG, Linlin WU, Zhiyu WANG, Liang CUI
-
Publication number: 20230286946Abstract: The present invention relates to difluoromethyl-pyridin-2-yl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for the manufacture of compounds according to the invention.Type: ApplicationFiled: August 4, 2021Publication date: September 14, 2023Applicant: Boehringer Ingelheim International GmbHInventors: Florian Montel, Yunhai Cui, Niklas Heine, Oliver Hucke, Radoslaw Lipinski, Stefan Peters, Janus Schreiber Larsen
-
Publication number: 20210147393Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (1) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.Type: ApplicationFiled: January 27, 2021Publication date: May 20, 2021Applicant: Boehringer Ingelheim International GmbHInventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
-
Patent number: 10941137Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.Type: GrantFiled: July 19, 2019Date of Patent: March 9, 2021Assignee: Boehringer Ingelheim International GmbHInventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
-
Patent number: 10675268Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: GrantFiled: November 2, 2018Date of Patent: June 9, 2020Assignee: Centrexion Therapeutics CorporationInventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
-
Publication number: 20200024261Abstract: The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.Type: ApplicationFiled: July 19, 2019Publication date: January 23, 2020Applicant: Boehringer Ingelheim International GmbHInventors: Janus Schreiber Larsen, Florian Binder, Yunhai Cui, Oliver Hucke, Radoslaw Lipinski, Florian Montel, Markus Ostermeier, Alexandre Perera, Stefan Peters
-
Publication number: 20190269650Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: ApplicationFiled: November 2, 2018Publication date: September 5, 2019Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
-
Patent number: 10166214Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: GrantFiled: August 24, 2017Date of Patent: January 1, 2019Assignee: Centrexion Therapeutics CorporationInventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
-
Publication number: 20180092880Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: ApplicationFiled: August 24, 2017Publication date: April 5, 2018Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
-
Patent number: 9789082Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: GrantFiled: May 18, 2016Date of Patent: October 17, 2017Assignee: Centrexion Therapeutics CorporationInventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
-
Publication number: 20170014381Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: ApplicationFiled: May 18, 2016Publication date: January 19, 2017Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doobs, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
-
Patent number: 9371282Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: GrantFiled: May 12, 2014Date of Patent: June 21, 2016Assignee: Centrexion Therapeutics CorporationInventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
-
Publication number: 20140343065Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: ApplicationFiled: May 12, 2014Publication date: November 20, 2014Applicant: Boehringer Ingelheim International GmbHInventors: Riccardo GIOVANNINI, Yunhai CUI, Henri DOODS, Marco FERRARA, Stefan JUST, Raimund KUELZER, Iain LINGARD, Rocco MAZZAFERRO, Klaus RUDOLF
-
Publication number: 20100234411Abstract: The present invention relates to novel pharmaceutical compositions based on telmisartan 1 and anticholinergics 2 processes for preparing them and their use for the treatment of respiratory diseases.Type: ApplicationFiled: July 14, 2008Publication date: September 16, 2010Applicant: BOEHRINGER INGELHEIM INTERMATIONAL GMBHInventors: Yunhai Cui, Wolfgang Wienen, Michael P. Pieper
-
Publication number: 20100015727Abstract: The present invention relates to a method for determining transport activity of a transport protein and its use for the identification of compounds which can modulate said transport activity.Type: ApplicationFiled: August 15, 2007Publication date: January 21, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Yunhai Cui
-
Patent number: 7229825Abstract: Described is a double-transfected cell line containing (a) a DNA sequence encoding an uptake transporter for organic anions, preferably OATP8, operatively linked with a promoter and (b) a DNA sequence encoding an export pump for organic anions or anionic conjugates, preferably the multidrug resistance protein 2 (MRP2), operatively linked with a promoter. Moreover, various uses of said cell line are described, preferably its use for the identification of transport inhibitors, e.g. drug candidates.Type: GrantFiled: December 5, 2003Date of Patent: June 12, 2007Assignee: Deutches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Yunhai Cui, Joerg Koenig, Dietrich Keppler
-
Publication number: 20060286041Abstract: The present invention relates to the use of MRP4 inhibitors for the treatment of respiratory diseases, pharmaceutical compositions containing them and processes for the preparation thereof.Type: ApplicationFiled: June 16, 2006Publication date: December 21, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Rolf Goeggel, Yunhai Cui
-
Publication number: 20050003538Abstract: Described is a double-transfected cell line containing (a) a DNA sequence encoding an uptake transporter for organic anions, preferably OATP8, operatively linked with a promoter and (b) a DNA sequence encoding an export pump for organic anions or anionic conjugates, preferably the multidrug resistance protein 2 (MRP2), operatively linked with a promoter. Moreover, various uses of said cell line are described, preferably its use for the identification of transport inhibitors, e.g. drug candidates.Type: ApplicationFiled: December 5, 2003Publication date: January 6, 2005Inventors: Yunhai Cui, Joerg Koenig, Dietrich Keppler